KLAS
Klas, a global leader in rugged edge technology solutions, is proud to unveil its most advanced vehicle data logging solution yet - the TRX D16. This cutting-edge device combines high-performance computing (HPC) and storage into a single platform, revolutionizing ADAS/AD development and data logging for both lab and in-vehicle use.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604506618/en/
TRX D16 from Klas - HPC ADAS/AD Development Server & Cloud Scale Data Logging (Photo: Business Wire)
The TRX D16 introduces transformational advancements to in-vehicle computing and logging and unleashes technology confined to the cloud or extremely large loggers up to this point. Now, high-end computing and logging can be fitted to any vehicle platform, allowing engineers to continue pushing the limits of ADAS/AD.
With TRX D16, automotive engineers gain a high-performance and customizable platform to accommodate the evolving vehicle sensor stack and support compute-intensive software development of AI/ML training, inference, and simulation. Furthermore, the platform delivers 200Gbps of sustained logging speeds and 480TB of data storage to capture data from high-speed ethernet-based cameras, with support for denser radar and lidar point cloud captures.
Designed rugged, the TRX D16 is equally at home in the lab and the vehicle. Engineers can transfer the entire development environment workbench to the vehicle for continued development and integration of new functionality with real-world drive test scenarios.
“As a single platform, the multi-purpose TRX D16 minimizes the number of disparate systems in the vehicle and reduces the effort of moving from the lab to the vehicle,” said Frank Murray, CTO of Klas. “By reducing the time spent preparing the vehicle, engineers can focus on productive tasks of real-world validation, which includes high-performance computing for AI testing. At a program level, the result is the improved time to market for new ADAS/AD functionality.”
TRX D16 key features
The TRX D16 is designed rugged to the highest specifications of MIL-STD-461 and 810G/H to withstand the extremes of temperature, vibration and shock.
- High performance computing: AMD EPYC™ 7713P (64 core) processor and up to 768GB of RAM, designed for embedded and harsh environments in vehicles.
- Open GPU options: Numerous GPU PCIe card options are supported, allowing for more flexible and cost-effective AI/ML development environments.
- Hot-swappable storage: 480 TB storage (16x SSDs) split over two removable cassettes allows test vehicles to return to the road in minutes with minimal IT effort.
- High disk write speeds: SAS4 SED drives, plus integrated RAID for secure data capture from an increased number of high-bandwidth sensors.
- High speed connectivity: 2x 100GbE interfaces to transfer valuable data to engineering HIL/SIL workbenches.
- Flexible expansion: 2x PCIe (Gen 4) interfaces for custom I/O - automotive Ethernet, FPGA based SmartNICs, GMSL/FPD-Link/GVIF based cameras, or storage.
To learn more about the TRX D16 HPC server and vehicle data logger or Klas, visit -
https://www.klasgroup.com/markets/automotive/l4-l5-data-logging/
About Klas
Klas is an engineering and design company with over 30 years of experience developing innovative rugged communications solutions for the network edge. The company specializes in integrating enterprise networking capabilities from global IT leaders with purpose-built hardware and software platforms designed to meet market demands and the most stringent environmental requirements. Klas collaborates with strategic partners, including Cisco, Dell, and Microsoft, to support edge deployments in Government, Transportation, and Automotive industries. For more information, visit www.klasgroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604506618/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom